Vitamin D Deficiency and Replacement on Pulmonary and Endocrine Function in SCI
Effects of Vitamin D Deficiency and Its Replacement on Pulmonary and Endocrine Function in Persons With SCI
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Vitamin D deficiency is prevalent in individuals with Spinal Cord Injury (SCI). Recent studies have linked vitamin D with the prevention and/or treatment of a wide range of diseases, including chronic lung diseases. Patients with chronic lung diseases appear to be at increased risk for vitamin D deficiency for reasons that are not clear. Chronic lung diseases such as asthma and chronic obstructive lung disease (COPD) have been linked to vitamin D on a genetic basis. A recent observational study found a significant association between vitamin D deficiency and decreased pulmonary function in a large able-bodied population. The exact mechanisms involved have not been identified, but it has been postulated that vitamin D possesses a range of anti-inflammatory properties involving modulation of oxidative stress, or, possibly, protease/antiprotease balance and tissue damage/repair, mechanisms that have been shown to be important in the pathogenesis of chronic lung diseases. The relationship between vitamin D and the immune system is of utmost importance given that individuals with high cervical lesions express many obstructive aspects of pulmonary physiology commonly observed in individuals with asthma, in whom airway inflammation represents an underlying pathophysiological mechanism.
In addition to a high prevalence of vitamin D deficiency, persons with SCI have a higher prevalence of insulin resistance (IR), impaired glucose tolerance (IGT) and diabetes mellitus (DM). In the general population, vitamin D deficiency has been shown to be associated with IR, IGT and DM. If treatment of vitamin D deficiency in persons with SCI is shown to be associated with improvement in insulin sensitivity and reductions in impaired glucose tolerance or DM, then progression to more severe carbohydrate disorders may be delayed or prevented.
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
New York
-
Bronx, New York, United States, 10468
- James J Peters VA Medical Center
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Part 1: Screening for Vitamin D Deficiency
Inclusion Criteria:
- Between the ages of 18 and 75,
- Chronic (>1 year) SCI; tetraplegia (C3-8), paraplegia, (T1-6)
Exclusion Criteria:
- Acute illness
- Acute drug or alcohol use
- Lack of mental capacity to give informed consent,
- Pregnancy,
- Currently receiving Vitamin D supplementation.
Part 2A: Vitamin D and Pulmonary Function
Inclusion Criteria:
- Between the ages of 18 and 75,
- Chronic SCI (>1 year, C3-T6)
- Vitamin D deficiency as defined as a value <20 ng/ml.
Exclusion Criteria:
- Smoking, active or history of smoking during life time,
- Any history of blast injuries to the chest,
- Active respiratory disease,
- Pregnancy,
- Lack of mental capacity to give informed consent.
- Recent (within 3 months) respiratory infection.
- Receiving medications known to alter airway caliber.
- Acute drug or alcohol use,
- Currently receiving Vitamin D supplementation > 1000 units/day.
Part 2B: Vitamin D, Carbohydrate Metabolism, and Insulin Resistance
Inclusion Criteria:
- Between the ages of 18 and 75,
- Chronic SCI (>1 year, C3-T6)
- Vitamin D deficiency as defined as a value <20 ng/ml,
- Insulin Resistance (IR), Impaired glucose tolerance (IGT), and/or Diabetes Mellitus (DM).
Exclusion Criteria:
- Pregnancy,
- Problems with the kidneys,
- Lack of mental capacity to give informed consent,
- Acute drug or alcohol use,
- Currently receiving Vitamin D supplementation > 1000 units/day.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
No Intervention: Screening Study
To determine the prevalence and severity of vitamin D deficiency and glucose tolerance in persons with chronic SCI.
|
|
|
Experimental: Pulmonary Arm
Vitamin D3 Supplementation and Pulmonary Function:
|
4000 IU/day or 2000 IU/day for 12 weeks
Other Names:
|
|
Experimental: Endocrine Arm
Vitamin D3 Supplementation and Endocrine Function: To determine the effect of vitamin D replacement therapy on carbohydrate metabolism and insulin resistance in persons with vitamin D deficiency (<20ng/ml) and IGT, mild DM (e.g. fasting serum glucose <140 mg/dL) and/or IR. |
4000 IU/day or 2000 IU/day for 12 weeks
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of SCI participants with vitamin D deficiency
Time Frame: Screening study (1 visit, 2 hours)
|
Vitamin D levels will be obtained during screening.
|
Screening study (1 visit, 2 hours)
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Pulmonary function improvement as measured by PFTs in SCI with increased vitamin D levels
Time Frame: Change from baseline at 6 months
|
Pulmonary function change will be measured in vitamin D deficient SCI subjects by spirometry and body plethysmography at baseline, 3 months, and 6 months.
|
Change from baseline at 6 months
|
Other Outcome Measures
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Pulmonary function improvement as measured by inflammation in SCI with vitamin D supplementation.
Time Frame: Change from baseline at 6 months
|
Pulmonary function change will be measured in vitamin D deficient SCI subjects by biomarkers of inflammation, such as FeNO, pH, and 8-isoprostane, at baseline, 3 months, and 6 months.
|
Change from baseline at 6 months
|
|
Impaired glucose tolerance (IGT) improvement in SCI with vitamin D supplementation
Time Frame: Change from baseline at 6 months
|
Vitamin D deficient SCI subjects with IGT and/or IR will undergo vitamin D replacement therapy.
Glucose and insulin levels will be measured at baseline, 3 months, and 6 months.
|
Change from baseline at 6 months
|
|
Musculoskeletal pain improvement with vitamin D supplementation
Time Frame: Change from baseline at 6 months
|
Vitamin D deficient SCI subjects will complete a pain survey at baseline, 3 months, and 6 months to assess musculoskeletal pain and how it may improve with vitamin D supplementation.
|
Change from baseline at 6 months
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: William Bauman, M.D., James J Peters VA Medical Center
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Central Nervous System Diseases
- Nervous System Diseases
- Wounds and Injuries
- Nutrition Disorders
- Trauma, Nervous System
- Spinal Cord Diseases
- Avitaminosis
- Deficiency Diseases
- Malnutrition
- Vitamin D Deficiency
- Spinal Cord Injuries
- Physiological Effects of Drugs
- Micronutrients
- Vitamins
- Bone Density Conservation Agents
- Calcium-Regulating Hormones and Agents
- Vitamin D
- Cholecalciferol
Other Study ID Numbers
Other Study ID Numbers
- BAU-11-092
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.